FDA Panel To Discuss Roche Holding AG Arthritis Drug July 29
LONDON, June 5 (Reuters) - Roche Holding AG's experimental arthritis drug Actemra will be considered for approval by a U.S. Food and Drug Administration panel on July 29. The new drug, which Roche views as a potential blockbuster, will be discussed by the watchdog's Arthritis Advisory Committee, according to the agency's telephone information line.